Critical Care Therapeutics Market Set to Grow at a CAGR of 5%

RnRMarketResearch.com adds “Critical Care Market to 2019 – Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific” new report on its database.

GBI Research estimates the overall critical care therapeutics market to have been worth $2.3 billion in 2012, having grown at a CAGR of 11% from $1.2 billion in 2006. The market is expected to grow at a CAGR of 5% during the forecast period to reach $3.2 billion in 2019. The double-digit market growth registered between 2006 and 2012 can be attributed primarily to the increasing demand for and cost of albumin, as well as the approval and launch of new products.

The growth of the overall critical care market during the forecast period is expected to be largely due to an increasing preference in the market for factor concentrates such as Riastap, Corifact, rFXIII (which has been launched in the European Union (EU) and is expected to be launched in the US later this year), expanded indications for Antithrombin (AT) III and factor concentrates, and rising demand for albumin from countries in Asia-Pacific.

Albumin Market to Remain the Leading Contributor to the Critical Care Market

With the world’s population ageing, especially in emerging markets, demand for albumin and plasma-derived products in general is expected to increase substantially during the forecast period. An ageing population is more likely to develop diseases, which is expected to generate more demand of blood derivatives. The market is expected to grow at a CAGR of 5% from $1.7 billion in 2012 to $2.4 billion in 2019. Demand showed year-on-year growth between 2006 and 2012, and this trend is expected to continue during the forecast period, due partially to increased therapeutic use and rising demand from Asia-Pacific countries, especially China. The leading players in the current albumin market are CSL, Baxter, Grifols, Octapharma, and Kedrion.

Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=96793

Weak Product Pipeline and Lack of Robust Clinical Data on the Use of PCC (Prothrombin complex concentrates), Factor Concentrates, and AT III Hinders Market Growth

The Research and Development (R&D) product pipeline for the critical care therapeutics market is currently weak. It comprises 13 molecules, most of which are in the early stages of development. A relatively low market value, small target population, and the lack of a large pool of patients on which to conduct clinical trials are some of the key reasons for the weakness of the product pipeline. Although most if not all approved products are used to manage bleeding in off-label indications, the lack of scientific data; and unproven safety, efficacy and cost-effectiveness are hindering use.

Stagnant innovation, a low prevalence rate and consequently limited patient availability for clinical trials are some of the major factors hindering the growth of the critical care market.

Scope

- Data and analysis regarding the critical care market in leading geographical locations – the US, the UK, Germany, France, Italy, Spain, and Japan and Asia-Pacific countries, including India, China and Australia.

- Annualized market data for the critical care market, including the individual markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2006 to 2012, with forecasts provided up to 2019.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume, and treatment usage patterns, such as disease population, diagnosis population and prescription population.

- Key drivers and restraints that have had a major impact upon the market.

- An overview of the competitive landscape of the global critical care market, including benchmarking for leading companies. Some of the key companies studied in this report are CSL, Octapharma, Baxter, Grifols, and LFB.

- Key M&A activities that took place in 2010 and 2011 in the critical care market.

Reasons to buy

- Align company product portfolios to markets with high growth potential.

- Build effective strategies to launch pipeline products, by identifying potential geographical markets.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms capable of producing first-in-class molecules which are safer and more efficacious

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=96793

Table of Content

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9

2 Introduction 10

3 Critical Care Market to 2019 - Global Overview 11

4 Critical Care Market to 2019 - Geographical Landscape 13
4.1 Introduction 13
4.2 The US - Critical Care Market 14
4.2.1 Revenue 14
4.3 Top Five European Countries - Critical Care Market 16
4.3.1 Revenue 16
4.4 Japan - Critical Care Market 18
4.4.1 Revenue 18

5 Critical Care Market to 2019 - Albumin Market 19
5.1 Introduction 19
5.2 Marketed Albumin Products 21
5.2.1 Buminate 21
5.2.2 Zenalb 21
5.2.3 Human Albumin Biotest 21
5.2.4 AlbuRx 22
5.2.5 Albuminar 22
5.2.6 Albutein 22
5.2.7 Albuked 23
5.2.8 Vialebex 23
5.2.9 Albunorm 23
5.2.10 AlbuRAAS 23
5.3 Revenue 24
5.4 Cost of Therapy 26
5.5 China 27
5.5.1 Introduction 27
5.5.2 Strict Regulatory Reforms Leading to Tighter Supply 27
5.5.3 Fragmented Market Dominated by Overseas Players 27
5.5.4 Price of Albumin Likely to Remain High 27
5.5.5 Conclusion 28
5.6 India 28
5.7 Australia 28
5.7.1 Introduction 28
5.7.2 Rising Albumin Demand 29
5.7.3 Australian Albumin Market 29
5.8 Market Drivers and Barriers 30
5.8.1 Market Drivers 30
5.8.2 Market Barriers 31

6 Critical Care Market to 2019 - Antithrombin Concentrate Market 32
6.1 Introduction 32
6.1.1 Marketed Antithrombin Concentrate Products 33
6.1.2 Revenue 38
6.1.3 Geographical Segmentation 40
6.1.4 Cost of Treatment 42
6.1.5 Treatment Usage Pattern 43
6.2 Drivers and Restraints 45
6.2.1 Drivers 45
6.2.2 Restraints 46

7 Critical Care Market to 2019 - Fibrinogen Concentrate Market 47
7.1 Introduction 47
7.2 Marketed Fibrinogen Concentrates 48
7.2.1 Haemocomplettan/Riastap 48
7.2.2 Clottafact 48
7.2.3 Other Marketed Fibrinogen Concentrates 49
7.2.4 Revenue 49
7.2.5 Geographical Segmentation 51
7.3 Market Segmentation 53
7.3.1 Cost of Treatment 55
7.4 Treatment Usage Pattern 56
7.5 Drivers and Barriers 59
7.5.1 Drivers 59
7.5.2 Barriers 60

8 Critical Care Market to 2019 - Prothrombin Complex Concentrate Market 61
8.1 Introduction 61
8.2 Marketed Products 63
8.2.1 Beriplex P/N 63
8.2.2 Confidex 63
8.2.3 Profilnine SD 63
8.2.4 Uman Complex DI 64
8.2.5 Kaskadil 64
8.2.6 Octaplex 500 64
8.2.7 Cofact 64
8.2.8 Feiba VH 64
8.2.9 Bebulin VH 65
8.3 Revenue 65
8.3.1 Revenue Breakdown 67
8.4 Geographical Segmentation 68
8.5 Cost of Therapy 69
8.5.1 Treatment Usage Pattern 71
8.6 Drivers and Restraints 72
8.6.1 Drivers 72
8.6.2 Barriers 73

9 Critical Care Market to 2019 - Factor XIII Concentrate Market 74
9.1 Introduction 74
9.2 Marketed Products 75
9.2.1 Fibrogammin / Corifact 75
9.3 Revenue 76
9.3.1 Geographical Segmentation 78
9.3.2 Cost of Treatment 81
9.3.3 Treatment Usage Pattern 83
9.4 Drivers and Restraints 85
9.4.1 Drivers 85
9.4.2 Restraint 86

10 Critical Care Market to 2019 - Research and Development Product Pipeline 87
10.1 Introduction 87
10.1.1 rFXIII (NovoThirteen) 89

11 Critical Care Market to 2019 - Competitive Landscape 90
11.1 CSL Limited 90
11.2 Baxter International Incorporated 90
11.3 Grifols, SA 90
11.4 Octapharma AG 90
11.5 Kedrion SpA 91
11.6 Biotest 91
11.7 Laboratoire Français de Fractionnement et de Biotechnologies 91
11.8 Bio Products Laboratory Limited 91
11.9 Sanquin Blood Supply Foundation 91
11.10 China Biologic Products, Incorporated 92
11.11 Hualan Biological Engineering, Incorporated 92
11.12 Shanghai RAAS Blood Products Company, Limited 92

12 Critical Care Market to 2019 - Strategic Consolidation 93
12.1 Grifols Acquisition of Talecris Biotherapeutics in June 2011 93
12.2 LFB Biotechnologies Acquisition of GTC Biotherapeutics in December 2010 93
12.3 ViroPharma Expands Licensing Agreement with Sanquin Blood Supply Foundation in January 2010 94

13 Critical Care Market to 2019 - Appendix 95
13.1 Market Definitions 95
13.2 Abbreviations 95
13.3 Bibliography 96
13.4 Research Methodology 98
13.4.1 Coverage 98
13.4.2 Secondary Research 98
13.4.3 Primary Research 99
13.5 Therapeutic Landscape 99
13.5.1 Market 101
13.6 Geographical Landscape 102
13.7 Pipeline Analysis 102
13.8 Competitive Landscape 102
13.8.1 Expert Panel Validation 102
13.9 Contact Us 102
13.10 Disclaimer 102

For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441

Website: http://www.rnrmarketresearch.com